GlassScriptPhysician profile
Meghan Harris
NPI 1235349812
$553,200.38
in general payments reported to CMS, 2019-2025
48 companies · $85K in 2025
The $85K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118K · 2020: $46K · 2021: $75K · 2022: $81K · 2023: $82K · 2024: $65K · 2025: $85K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $185K · Honoraria: $20K · Food and Beverage: $17K · Travel and Lodging: $8,486 · Consulting Fee: $2,336 · Education: $17.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $185,232.50 |
| Honoraria | $19,810.00 |
| Food and Beverage | $16,925.96 |
| Travel and Lodging | $8,485.83 |
| Consulting Fee | $2,336.00 |
| Education | $17.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $99,126.40 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Abbvie INC. | $73,809.36 | 2021-2025 | |
| Horizon Therapeutics Plc | $56,421.04 | 2021-2023 | Uplizna |
| Genentech USA, INC. | $49,822.98 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Alexion Pharmaceuticals, INC. | $49,571.00 | 2019-2025 | Ultomiris, Soliris |
| Amgen INC. | $44,801.50 | 2019-2025 | Uplizna, Aimovig |
| Tg Therapeutics, INC. | $43,312.52 | 2023-2025 | |
| Genzyme Corporation | $42,173.90 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $22,997.54 | 2020-2025 | Acthar |
| Biohaven Pharmaceuticals, INC. | $15,947.17 | 2021 | |
| Acorda Therapeutics, INC | $11,298.10 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $11,273.86 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $9,059.55 | 2022 | |
| Celgene Corporation | $8,204.50 | 2019-2025 | Zeposia |
| Eisai INC. | $2,722.89 | 2023-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $2,389.16 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $2,204.11 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $1,209.87 | 2022-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $1,161.34 | 2019-2025 | |
| Pfizer INC. | $824.97 | 2023-2025 | |
| Lilly USA, LLC | $765.98 | 2019-2025 | Kisunla, Emgality, Amyvid |
| E.R. Squibb & Sons, L.L.C. | $737.68 | 2021-2024 | Zeposia |
| Allergan, INC. | $644.85 | 2019-2022 | |
| Mdd US Operations, LLC | $641.23 | 2022-2025 | Gocovri, Apokyn, Xadago |
| Otsuka America Pharmaceutical, INC. | $467.13 | 2023-2025 | Rexulti, Nuedexta |
| Amneal Pharmaceuticals LLC | $337.92 | 2019-2025 | Crexont, Rytary |
| Teva Pharmaceuticals USA, INC. | $307.60 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Lundbeck LLC | $148.22 | 2021-2025 | Rexulti, Vyepti |
| Kyowa Kirin, INC. | $136.52 | 2021-2023 | Nourianz |
| Ucb, INC. | $102.64 | 2023-2025 | Zilbrysq, Briviact |
| Genentech, INC. | $102.52 | 2019 | |
| Merz Pharmaceuticals, LLC | $51.37 | 2025 | Xeomin, Ampyra, Inbrija |
| Cycle Pharmaceuticals INC | $49.57 | 2025 | Tascenso Odt |
| Adamas Pharmaceuticals, INC. | $48.76 | 2021 | |
| Axsome Therapeutics, INC. | $48.62 | 2025 | Symbravo |
| Impel Pharmaceuticals INC. | $36.47 | 2022 | |
| Portola Pharmaceuticals, LLC | $33.07 | 2019 | |
| Supernus Pharmaceuticals, INC. | $32.95 | 2019 | |
| Hospira, INC. | $30.27 | 2024-2025 | |
| Grifols USA, LLC | $23.39 | 2025 | Gamunex-C |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.75 | 2025 | Rexulti |
| Boston Scientific Corporation | $18.03 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.92 | 2025 | Wainua |
| Janssen Pharmaceuticals, INC | $17.90 | 2025 | |
| Csl Behring | $17.08 | 2025 | Hizentra |
| Insightec,INC | $17.01 | 2024 | Exablate |
| Emd Serono, INC. | $13.17 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.